Medtronic (MDT) 10-Q2024 Q3 Quarterly report

Filed: 27 Feb 24, 4:16pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: ACM, blood, called, Department, EndoFlip, endotracheal, equitable, greater, highlighted, honor, imposition, Justice, MAC, McGRATH, Microstream, Nellcor, OxiMax, raw, regular, Shiley, Sync, Topic, tracheostomy, video, volume

Removed: applied, apply, assert, Bard, comfort, consortium, consumer, customary, decline, defend, extend, fraud, implantation, improved, manufactured, Northern, obligation, prejudice, protection, release, resolve, select, settle, solution, superficial, supplied, Targeted, thermal, Title, unique, VenaSeal, Virginia, WACC, warn, warranty, West

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated MDT transcripts

MDT similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

Certification of Chief Executive Officer

Pursuant to Section 906 of the

Sarbanes-Oxley Act of 2002

In connection with this quarterly report on Form 10-Q of Medtronic plc for the quarter ended January 26, 2024, the undersigned hereby certifies, in his capacity as Chief Executive Officer of Medtronic plc, for purposes of 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)The report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2)The information contained in this report fairly presents, in all material respects, the financial condition and results of operations of Medtronic plc.


February 27, 2024			/s/ Geoffrey S. Martha
			Geoffrey S. Martha
			Chief Executive Officer